Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | CALML3 | P27482 | 6/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609999 | 0.80 | MAOA (0.61) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL6610002 | 0.79 | MAOA (0.53) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL2897089 | 0.78 | CALML3 (0.49) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL3042615 | 0.77 | MAOA (0.49) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL2898570 | 0.76 | MAOA (0.49) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL3043507 | 0.76 | MAOA (0.49) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL2897205 | 0.76 | MAOA (0.40) | MAOAMAOBCALML3 | |
| SCHEMBL2896944 | 0.75 | KDM4E (0.37) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL2890306 | 0.75 | MAOA (0.58) | MAOAMAOBCALML3CYP2C19CYP3A4 | |
| SCHEMBL27592138 | 0.74 | MAOA (0.49) | MAOAMAOBCALML3CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | claimed |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | MAOA 1717/4885MAOB 2038/4885CALML3 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.